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Abstract: Diets high in calories and sweetened foods with disaccharides frequently lead to 
exaggerated postprandial spikes in blood glucose. This state induces immediate oxidant 
stress and free radicals which trigger oxidative stress-linked diabetic complications. One of 
the  therapeutic  approaches  for  decreasing  postprandial  hyperglycemia  is  to  retard 
absorption of glucose by the inhibition of carbohydrate hydrolyzing enzymes, α-amylase 
and α-glucosidases, in the digestive organs. Therefore, the inhibitory activity of Korean 
onion (Allium cepa L.) extract against rat intestinal α-glucosidases, such as sucrase, maltase, 
and porcine pancreatic  α-amylase were investigated in vitro  and in vivo. The content of 
quercetin in ethyl alcohol extract of onion skin (EOS) was 6.04 g/100 g dried weight of 
onion skin. The in vitro half-maximal inhibitory concentrations (IC50) of EOS and quercetin, 
a  major  phenolic  in  onion,  on  rat  intestinal  sucrase  were  0.40  and  0.11  mg/mL, 
respectively. The postprandial blood glucose lowering effects of EOS and quercetin were 
compared to a known type 2 diabetes drug (Acarbose), a strong α-glucosidase inhibitor in 
the Sprague-Dawley (SD) rat model. In rats fed on sucrose, EOS significantly reduced the 
blood  glucose  spike  after sucrose loading.  The  area under the blood  glucose-time  curve 
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(AUClast) in EOS-treated SD rats (0.5 g-EOS/kg) was significantly lower than in untreated 
SD rats (259.6 ±  5.1 vs. 283.1 ±  19.2 h· mg/dL). The AUClast in quercetin-treated SD rats  
(0.5 g-quercetin/kg) was similar to in EOS-treated group (256.1 ±  3.2 vs. 259.6 ±  5.1 h· mg/dL). 
Results from this study indicates that although quercetin does have blood glucose lowering 
potential  via  α-glucosidase  inhibition,  there  are  other  bioactive  compounds  present  in  
onion  skin.  Furthermore,  the  effects  of  two  weeks  administration  of  EOS  in  a  high  
carbohydrate-dietary  mixture  (Pico  5053)  on  sucrase  and  maltase  activities  in  intestine 
were evaluated in SD rat model. Compared to the upper and middle parts of intestine, the 
activities of sucrase in the lower parts of intestine remained significantly higher after two 
weeks  of  EOS  treatment.  These  results  indicate  that  EOS  may  improve  exaggerated 
postprandial spikes in blood glucose and glucose homeostasis since it inhibits intestinal 
sucrase and thus delays carbohydrate absorption, although clinical trials are needed. 
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1. Introduction 
Recent  studies  indicate  that  about  one-third  of  American  adults  and  two-thirds  of  coronary  
artery  disease  (CAD)  patients  have  abnormal  glucose  homeostasis  [1,2].  The  highly  processed,  
calorie-dense,  nutrient-depleted  diet  favored  in  the  current  American  culture  frequently  leads  to 
exaggerated postprandial spikes in blood glucose. This state, called postprandial hyperglycemia, induces 
immediate oxidant stress, which increases in direct proportion to the increase in glucose after a meal [3].  
Hyperglycemia, a typical symptom in non-insulin dependent diabetes mellitus (NIDDM, type 2 
diabetes) patients, is a condition characterized by a rapid rise in blood glucose levels and is due to 
hydrolysis  of  starch  by  pancreatic  α-amylase  and  absorption  of  glucose  in  the  small  intestine  by  
α-glucosidases [4]. The intestinal absorption of dietary carbohydrates such as maltose, sucrose, and 
starch is carried out by a group of α-glucosidases. One of the therapeutic approaches for decreasing 
postprandial hyperglycemia is to retard digestion of glucose by the inhibition of these carbohydrate 
hydrolyzing  enzymes,  α-glucosidases,  in  the  digestive  tract  [4].  Therefore,  inhibition  of  these 
carbohydrate-hydrolyzing enzymes can significantly decrease the postprandial hyperglycemia after a 
mixed carbohydrate diet and can be a key strategy in the control of diabetes mellitus [5].  
Postprandial  hyperglycemia  has  been  linked  to  the  onset  of  diabetic  complications  in  NIDDM 
patients and triggers the generation of free radicals and oxidation-related damage in the retina, renal 
glomerulus and peripheral nerves [6,7]. Studies have shown that the glucose-induced increased levels 
of mitochondrial reactive oxygen species (ROS) produced by the mitochondrial electron transport 
chain seems to be the causal link between elevated levels of glucose and the pathways responsible for 
hyperglycemia-induced  vascular  complications  [6,8].
  One  ongoing  study,  the  European  Study  to 
Prevent Non-Insulin Dependent Diabetes (STOP-NIDDM), seems to show that treatment of people 
with impaired glucose tolerance (IGT) (based on postprandial blood sugars) with the drug acarbose 
(Precose®  or  Prandase®)  helped  prevent  the  onset  of  type  2  diabetes  and  reduced  the  risks  of 
cardiovascular problems [9]. Int. J. Mol. Sci. 2011, 12                       
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Important  plant  foods  in  traditional  diet  such  as  herbs,  onion  and  beans  have  high  phenolic 
phytochemicals. Among these plant foods Allium species, onions and garlic have long been used for a 
large  range  of  purposes  including  medicine,  nutrition,  flavoring,  condiment,  foodstuff,  and  the 
treatment  of  common  ailments  as  folk  medicine  [10].  Recent  research  has  reported  that  phenolic 
phytochemicals  from  onion  have  blood  glucose  lowering  effect  and  high  antioxidant  activity  in 
alloxan-induced  diabetic  rat  [11–13].  Further  it  is  rich  in  flavonoids  such  as  quercetin  and  sulfur 
compounds,  such  as  allyl  propyl  disulfide  that  have  perceived  benefits  to  human  health  [14]. 
Epidemiological  studies  have  also  shown  that  the  intake  of  certain  types  of  flavonoids,  including 
quercetin and myricetin is inversely associated with the risk of incident type 2 diabetes [15]. Quercetin, 
Isoquercitrin and rutin have shown inhibitory activities on α-glucosidase from the rat intestine [16]. 
Therefore, minimally processed and phenolic phytochemical enriched plants such as vegetables, fruits, 
nuts, seeds, and grains generally increase postprandial glucose and triglycerides to a lesser degree than 
do processed foods [17]. 
The  effect  of  quercetin  on  hyperglycemia  is  already  well-determined  [16].  However,  
anti-hyperglycemic effect of onion skin extracts (EOS) and the long-term effects of EOS treatment on 
intestinal  enzyme activities have not  been investigated. The effects of  EOS administration on  the 
absorption of glucose via interruption and induction of intestinal α-glucosidases are also not known. 
Therefore, the aim of this study is to investigate the effects of EOS on hyperglycemia and long term 
EOS  treatment  in  changes  of  the  activities  of  small  intestinal  α-glucosidases  on  the  brush  border 
membranes. Clear knowledge of the mode of action of onion extract will contribute towards better 
understanding of the real effect of various onion products towards type 2 diabetes management. To 
determine the above, in this study, we (i) Prepared EOS by ethyl alcohol extraction; (ii) Compared  
the  inhibitory  activity  of  EOS  to  that  of  quercetin  against  α-amylase  and  α-glucosidases  
(anti-hyperglycemia potential); (iii) Evaluated the postprandial blood glucose lowering effect of EOS 
after sucrose loading in a Sprague-Dawley (SD) rat model; and (iv) Measured changes in intestinal 
enzyme activities after 2 weeks of EOS administration in SD rat model. 
2. Results and Discussion  
2.1. HPLC Analysis of EOS 
Our previous studies have shown that the content of quercetin in onion skin extract has outstanding 
levels  of  quercetin  comparing  to  the  onion  pulp  [18].  Kim  and  Kim  reported  significant  increase 
amounts of quercetin, 16.83, 2.67, 0.95, and 0.35 mg/g in the methyl alcohol extracts of onion skin, 
outer, middle and core parts respectively, with greater distance from the core [10].  
Therefore, ethyl alcohol extract of onion skin (EOS) was prepared for further studies, and the major 
phenolic, quercetin was identified in the extracts using HPLC (Table 1). EOS had high concentrations 
of quercetin (6041.8 mg/100  g  dried  weight  of onion  skin). These results  suggest  that 95% ethyl 
alcohol (edible) extract of onion skin which has high quercetin content has the potential to contribute 
as a useful food application method for producing and enhancing bioactive food components such as 
quercetin in safety.  Int. J. Mol. Sci. 2011, 12                       
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Table 1. Quercetin content (mg/100 g-dried weight of onion skin) analyzed by HPLC in 
ethyl alcohol extracts of onion skin (EOS). 
 
Quercetin 
(mg/100 g-dried weight of onion skin) 
EOS  6041.8 
2.2. α-Amylase and α-Glucosidases Inhibition  
The α-glucosidase inhibitors, which interfere with enzymatic action in the brush-border of the small 
intestine, could inhibit the liberation of D-glucose from oligosaccharides and disaccharides, resulting in 
delaying glucose absorption and decreasing postprandial plasma glucose levels [19]. Previous research 
with  onion  extracts  reported  that  methyl  alcohol  extracts  of  onion  had  high  microbial  
α-glucosidase  (from  Baker’s  yeast)  inhibitory  activity  [20].  It  has  been  reported  that  most  yeast  
α-glucosidase inhibitors did not show inhibitory activity against mammalian α-glucosidase due to the 
difference of molecular recognition in the binding site of the enzymes [21], Therefore, in order to have 
better  health  relevance,  mammalian  α-glucosidases  (from  rat  intestine)  were  used  to  estimate  the 
inhibitory activities of  EOS and quercetin in this study. As a result, EOS had the highest sucrase 
inhibitory activity (0.40) followed by α-glucosidase (1.27), maltase (2.02), and α-amylase (IC50 of 
>3.00 mg/mL) (Table 2). The quercetin also showed potent sucrase inhibitory activity with an IC50 
value of 0.11 mg/mL (Table 2), indicating a potential role as an active compound in onion extract. 
However, the content of quercetin in EOS was 6% of dried weight of onion skin (Table 1). This result 
suggests that sucrase inhibitory activity of EOS did not correlate with quercetin content and may be 
potentially linked to other unknown bioactive compounds in onion skin extract.  
Based on these results, data trends for α-glucosidases inhibitory activities in EOS have important 
implications for the development and new design of onion-based functional foods.  
Table  2.  Comparison  of  inhibitory  activities  (IC50)  of  EOS  (mg/mL)  and  Quercetin 
(mg/mL) against α-glucosidase, α-amylase, sucrase, and maltase in vitro. 
    IC50 (mg/mL) 
EOS 
α-Glucosidase  1.27 
α-Amylase  >3.00 
Sucrase  0.40 
Maltase  2.02 
Quercetin 
α-Glucosidase  0.15 
α-Amylase  >0.60 
Sucrase  0.11 
Maltase  0.07 
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2.3. In Vivo Blood Glucose Lowering Effect of EOS and Quercetin 
EOS  and  quercetin  showed  significant  inhibition  against  α-glucosidases  especially  for  sucrase, 
which are membrane-bound enzymes at the epithelia of the small intestine and key enzymes of sucrose 
digestion (Table 2). Inhibition of sucrase may lead to a delayed and reduced rise in postprandial blood 
glucose levels.  
To confirm in vitro sucrase inhibitory activity of samples, the in vivo blood glucose reducing effects 
of  EOS  and  its  bioactive  compound  quercetin  were  evaluated  with  SD  rats  and  the  results  are 
illustrated in Figure 1. In SD rats, EOS exerted a statistically significant decrease (p < 0.01) of the 
blood glucose at half an hour after sucrose loading. Quercetin significantly reduced (p < 0.01) the 
postprandial hyperglycemia caused by sucrose  loading to  an extent less than that observed in  the 
acarbose administered group (p < 0.001) (Figure 1) . 
Figure 1. Effect of EOS (A) and quercetin (B) on sucrose loading test. After fasting for 24 h, 
5-week-old, male SD rats were orally administered with sucrose solution (2.0 g/kg) with or 
without samples (EOS, Ethyl alcohol extract of onion skin: Positive control: Acarbose). 
Each point represents mean  S.D. (n = 5). *p < 0.05, **p < 0.01, and ***p < 0.001 
compared to different samples at the same concentration by unpaired Student’s t-test. 
 
(A)              (B) 
These data clearly demonstrate that the presence of phenolic phytochemicals such as quercetin in 
onion may play an important role in anti-hyperglycemic activity, and result in a reduction of blood 
glucose levels, which is in agreement with previous study by Kim et al. [10]. Furthermore, recent 
research  has  reported  that  phenolic  phytochemicals  from  onion  have  high  antioxidant  activity  in 
alloxan-induced diabetic rat  [11–13]. Any dietary management  of hyperglycemia linked to  type 2 
diabetes  and  related  complications  from  oxidative  dysfunction  can  benefit  from  specific  enzyme 
inhibitory activity combined with antioxidant activity in the same whole food extracts. Insights from 
this  study  indicate  that  EOS  have  blood  glucose  lowering  effect  and  high  content  of  quercetin 
antioxidant  and  therefore  have  the  potential  to  contribute  to  the  reduction  of  hyperglycemia  and 
oxidative stress-induced diabetic complications. Int. J. Mol. Sci. 2011, 12                       
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The  pharmacokinetic  parameters  of  SD  rats  administered  with  EOS,  quercetin  or  acarbose  are 
shown in Table 3. The EOS treatment at 0.5 g/kg body weight significantly decreased area under the 
blood glucose-time curve (AUC) (p < 0.001) and Cmax (p < 0.01) blood glucose in rats that ingested 
sucrose compared to control. AUC glucose was lowest after acarbose. There was a decrease of 11% 
and 11% in EOS administration group compared to control group in the Cmax and AUClast respectively. 
The  quercetin  treatment at  0.5 g/kg body weight  also  significantly decreased blood  glucose  AUC 
(9.6%, p < 0.01) and Cmax (19.1%, p < 0.05) blood glucose in rats that ingested sucrose. These data 
suggest that although quercetin has blood glucose reduction effect, there are possibly other bioactive 
compounds  present  in  onion  skins  that  contribute  towards  the  observed  blood  glucose  lowering  
effect of EOS.  
On the other hand, the time of peak plasma concentration (Tmax) of glucose significantly increased 
in  rats  treated  with  EOS  (1.0  h,  p  <  0.05)  compared  to  control  (0.6  h)  when  sucrose  was  orally 
administered to them (Table 3). These results may demonstrate the positive effects of EOS against 
postprandial spikes in blood glucose resulting from high sucrose ingestion and absorption. It suggests 
that  EOS with  high blood  glucose  lowering  effect  may  be  due to  delaying  absorption  of  glucose 
through inhibition of sucrase in the intestinal tract. 
Table 3. Pharmacokinetic parameters of SD control rats or after administration of EOS, 
quercetin, and acarbose after sucrose ingestion. 
    PK parameters 
    AUClast (h· mg/dL)  Cmax (mg/dL)  Tmax (h) 
Sucrose  Control  283.1 ±  19.2  177.8 ±  15.9  0.5 ±  0.0 
  Acarbose (5.0 mg/kg)  230.7 ±  15.2**  128.4 ±  18.4**  0.7 ±  0.3 
  Quercetin (0.5 g/kg)  256.1 ±  3.2*  144.0 ±  3.4**  0.5 ±  0.0 
Sucrose  Control  290.6 ±  7.3  171.2 ±  7.2  0.6 ±  0.2 
  Acarbose (5.0 mg/kg)  205.1 ±  29.4***  111.0 ±  15.8***  1.2 ±  0.8 
  EOS(0.5 g/kg)  259.6±  5.1***  153.2 ±  9.3**  1.0 ±  0.0* 
2.4. Sucrase and Maltase Activities in the Intestine 
As shown in Figure 1(A), the blood glucose levels of the EOS-treated group were significantly 
lower than those of the control groups at 30 min of measurement, but not significant after 30 min. The 
time of peak plasma concentration (Tmax) of glucose significantly increased in rats treated with EOS 
(1.0 h, p < 0.05) compared to control (0.6 h) when sucrose was orally administered to them (Table 3). 
Therefore, it  was  hypothesized that  EOS with  high blood  glucose lowering effect  may be  due to 
delaying  absorption  of  glucose through inhibition  of sucrase  in  the  intestinal tract.  The  effects of  
two weeks administration of EOS in a high carbohydrate-dietary mixture (Pico 5053, Table 4) on 
sucrase and maltase activities in intestine were evaluated in SD rat model.  Int. J. Mol. Sci. 2011, 12                       
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Table 4. Composition of the diets (g/kg). 
  Control  EOS 
Corn Starch  661  661 
Casein  226  226 
Soybean Oil  60  60 
Vitamin Mix
1  31  31 
Mineral Mix
2  9  9 
Calcium Phospahte  10  10 
Sodium chloride  3  3 
Sample  0  100 
1AIN-93VX vitamin mix (Oriental Yeast Co., Tokyo, Japan). 
2AIN-93G mineral mix (Oriental Yeast Co., Tokyo, Japan). 
To prove intestinal α-glucosidases inhibition by EOS treatment, the sucrase and maltase activities in 
the intestinal tract were evaluated with SD rats and the results are illustrated in Figure 2. The activity 
of maltase was not inhibited by EOS administration (Figure 2B), but sucrase activity decreased in 
EOS-treated SD rats, and such decrease was found in the upper and middle of the three areas of the 
intestine (Figure 2A). Compared to the upper and middle parts of intestine, the activities of sucrase in 
the lower parts of intestine remained significantly higher after two weeks of EOS treatment, but no 
significant differences in maltase activities in whole part of intestine (Figure 2). These activities might 
be  up-regulated  by  EOS,  which  are  in  agreement  with  previous  study  with  voglibose  
α-glucosidase inhibitor by Yasuda et al. [22]. This suggests that two weeks treatment with EOS may 
increase the expression of sucrase in the lower part of intestine in compensation for the inhibition their 
activities  in  the  upper  and  middle  parts.  Indeed  modern  studies  indicate  that  Cinnamon  a  
calorie-free  herb  rich,  when  added  to  a  high-glycemic-index  meal,  significantly  reduces  the  
post-prandial glucose excursion, partly by slowing gastric emptying [23]. Recent study by Yasuda et al. 
also reported that the expressions of protein and mRNA of the sucrase-isomaltase (SI) complex were 
significantly higher in voglibose treated rats than in non-treated rats, especially in the lower part of the 
intestine [23]. 
Figure  2.  Effects  of  EOS  administration  on  sucrase  (A)  and  maltase  (B)  activities 
(nmol/min/mg protein) in different parts of intestine. The results represent the mean ±  S.D. 
of values obtained from three measurements. Bar with different letters indicate statistical 
significance of differences among groups at p < 0.05 by Duncan’s test.  
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Therefore, these results indicate that EOS may improve exaggerated postprandial spikes in blood 
glucose and glucose homeostasis due to the inhibition of sucrase in the upper and middle part of 
intestine and thus delays carbohydrate absorption, but such detailed relationship between EOS and the 
expression of SI complex should be examine in the future study. 
3. Experimental Section  
3.1. Materials 
Korean onion (Allium cepa L.) was purchased from a local market in Daejeon, Korea. The dried skin 
of onion was identified by one of authors (Dr. Young-In Kwon). A voucher specimen (BFC O10012) 
was deposited at the Bioactive Food Components Lab. (BFCL) of the College of Life Science and Nano 
Technology,  Hannam  University.  Porcine  pancreatic  α-amylase  (EC  3.2.1.1),  rat  intestinal  acetone 
powders  of  α-glucosidase  (EC  3.2.1.20),  quercetin  (3,3’,4’,5,7-Pentahydroxyflavone  dihydrate)  and 
soluble  starch  (S9765-250G)  were  also  purchased  from  Sigma-Aldrich  Co.  (St.  Louis,  MO,  USA). 
Unless noted, all chemicals were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). 
3.2. Preparation of Onion Extracts  
After  peeling  of  onion  (Allium  cepa  L.)  with  a  knife,  100  g  of  skin  were  mashed  and  stirred 
respectively in 1000 mL of 95% concentration of ethyl alcohol at 40 ° C for 24 h. The skin extract (EOS) 
were then filtered through a Whatman # 2 filter, centrifuged at 7000 ×  g for 1 h, vacuum-evaporated  
at 45 ° C, freeze-dried and kept at −70 °C until analysis. 
3.3. HPLC Analysis of Quercetin  
A volume of 2 mL of ethyl alchol extract of onion skin were filtered through a 0.2 µm syringe filter. 
The quercetin in the extract were analyzed using HPLC [24], (Tosoh 8010 series; Tosoh Corporation, 
Tokyo, Japan) equipped with a diode-array UV-vis detector (UV 8010; Tosoh Corporation) at 363 nm, 
and TSKgel-ODS 80 (15 cm ×  7.6 mm) column (TSK ODS 80; Tosoh Corporation). The mobile phase 
used a water- acetonitrile mixture containing 0.05% phosphoric acid, where the flow rate and sample 
injection volume were fixed at 1.0 mL/min and 20 µL, respectively. The solvents used for gradient 
elution were (A) water:acetonitrile (95:5, v/v) and (B) water:acetonitrile (50:50, v/v). The solvent (B) 
was increased to 30% for the first 20 min and to 80% over the next 20 min, then decreased to 10% for 
the next 5 min and was maintained for the next 10 min (total run time, 55 min). As reference ingredient, 
pure standard of quercetin (purchased from Sigma Chemical Co.) in 100% methanol was used to 
calibrate the standard curve and retention times. 
3.4. Preparation of Crude Enzyme Extracts 
The small intestine was cut transversely into three segments (upper, middle, and lower part) of 
roughly equal length. Each segment was flushed with ice-cold phosphate buffered saline, frozen in 
liquid nitrogen, and stored at −80 °C . Each section of intestine was homogenized in 10 mL of 100 mM 
potassium phosphate buffer, pH 6.8, with a homogenizer (Ultra-Turrax T25, Janke & Kunkel Co., Int. J. Mol. Sci. 2011, 12                       
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Staufen, Germany). After centrifugation at 3000 ×  g for 10 min, the supernatant obtained was used as 
crude enzyme solution. 
3.5. α-Amylase Inhibition Assay 
To evaluate the potency of onion (Allium cepa L.) extracts the dose dependency of onion skin 
extract (ES) and quercetin on α-amylase was measured using different concentrations (between 1.0 and 
3.0 mg/mL). Porcine pancreatic  α-amylase inhibition  referred to  the method  of  Kwon  et  al.  [25]. 
Sample solution (200 μL) and 0.02 M sodium phosphate buffer (pH 6.9 with 0.006 M sodium chloride, 
500 μL) containing α-amylase solution (0.5 mg/mL, 5.0 MU/mL) were incubated at 25 °C  for 10 min. 
After pre-incubation, 500 μL of a 1% starch solution in 0.02 M sodium phosphate buffer was added. 
The reaction mixture was then incubated at 25 ° C for 10 min. The reaction was stopped with 1.0 mL of 
dinitrosalicylic acid (DNS). The reaction mixture was then incubated in a boiling water bath for 5 min 
and cooled to room temperature. The reaction mixture was then diluted after adding distilled water, 
and absorbance was measured at 540 nm with ELISA micro-plate reader (SUNRISE; Tecan Trading 
AG, Saltzburg, Austria). 
 
3.6. α-Glucosidase Inhibition Assay 
To evaluate the potency of onion (Allium cepa L.) extracts, the dose dependency of onion skin extract 
(ES) and quercetin on rat intestinal α-glucosidase was measured using different concentrations (between 
1.0 and 3.0 mg/mL). Rat intestinal α-glucosidase assay referred to the method of Kwon et al. [25] with 
slight modification. A total of 1 g of rat-intestinal acetone powder was suspended in 3 mL of 0.9% saline, 
and the suspension was sonicated 12 times for 30 s at 4 °C . After centrifugation (10,000  g, 30 min,  
4 °C ), the resulting supernatant was used for the assay. Sample solution (50 µL) and 0.1 M phosphate 
buffer (pH 6.9, 100 µL) containing glucosidase solution (1.0 U/mL) was incubated at 25 °C  for 10 min. 
After pre-incubation, 5 mM p-nitrophenyl-α-D-glucopyranoside solution (50 µL) in 0.1 M phosphate 
buffer (pH 6.9) was added to each well at timed intervals. The reaction mixtures were incubated at 25
 °C  
for 5 min. Before and after incubation, absorbance was read at 405 nm and compared to a control which 
had 50 µL of buffer solution in place of the extract by micro-plate reader (SUNRISE; Tecan Trading AG, 
Saltzburg,  Austria).  The  α-glucosidase  inhibitory  activity  was  expressed  as  inhibition  %  and  was 
calculated as follows: 
 
3.7. Maltase and Sucrase Activity Assay 
Rat-intestinal crude enzyme (1.0 g) was suspended in 3 mL of 0.9% saline, and the suspension was 
sonicated twelve times for 30 s at 4 °C . After centrifugation (10,000  g, 30 min, 4 °C ), the resulting 
supernatant  was  used  for  the  assay.  Maltase  and  sucrase  activities  were  assayed  by  modifying  a 
method developed by Dahlqvist [26]. The activity was determined by incubating a solution of crude Int. J. Mol. Sci. 2011, 12                       
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enzyme (50 µL), 0.1 M phosphate buffer (pH 7.0, 100 µL) containing 0.4 mg/mL sucrose or maltose at 
37 °C  for 30 min. The reaction mixture was heated in a boiling water bath to stop the reaction for  
10 min, and then the amount of liberated glucose was measured by the glucose oxidase method [26].  
3.8. Maltase and Sucrase Inhibition Assay 
The  crude  enzyme  solution  prepared  from  rat  intestinal  acetone  powder  Sigma-Aldrich  Co.  
(St. Louis, MO, USA) was used as the small intestinal maltase and sucrase, showing specific activities 
of 0.70 and 0.34 units/mL, respectively. Rat-intestinal acetone powder (1.0 g) was suspended in 3 mL 
of 0.9% saline, and the suspension was sonicated twelve times for 30 s at 4 °C . After centrifugation 
(10,000  g, 30 min, 4 °C ), the resulting supernatant was used for the assay. Maltase and sucrase 
inhibitory activities were assayed by modifying a method developed by Dahlqvist [26]. The inhibitory 
activity  was  determined by  incubating  a solution  of an enzyme (50 µL), 0.1 M  phosphate buffer  
(pH 7.0, 100 µL) containing 0.4 mg/mL sucrose or maltose, and a solution (50 µL) with various 
concentrations of sample solution (between 0.05 mM and 1.0 mM) at 37 °C  for 30 min. The reaction 
mixture was heated in a boiling water bath to stop the reaction for 10 min, and then the amount of 
liberated  glucose  was  measured  by  the  glucose  oxidase  method  [26].  The  inhibitory  activity  was 
calculated from the formula as follows. Inhibition (%) = (C − T)/C ×  100, where C is the enzyme 
activity without inhibitor and T is the enzyme activity with inhibitor. 
3.9. Sugar Loading Test 
Effect  on  hyperglycemia  induced  by  carbohydrate  loads  in  Sprague-Dawley  (SD)  rats  was 
determined by the inhibitory action of EOS, quercetin and Acarbose on postprandial hyperglycemia. 
Five week-old male SD rats were purchased from Joongang Experimental Animal Co. (Seoul, Korea) 
and fed a solid diet (Samyang Diet  Co., Seoul,  Korea) for one week. The rats  were housed in  a 
ventilated room at 25 ±  2 °C  with 50 ±  7% relative humidity, and under an alternating 12 h light/dark 
cycle. After 6 groups of 5 male SD rats (180–200 g) were fasted for 24 h, 2.0 g/kg of sucrose were 
orally administrated concurrently with 0–500 mg/kg inhibitors (EOS or quercetin or Acarbose). The 
blood  samples  were  then  taken  from  the  tail  after  administration  and  blood  glucose  levels  were 
measured at 0, 0.5, 1, and 2 h. The glucose level in blood was determined by glucose oxidase method 
and compared with that of the control group, which had not taken the inhibitors. The parameters for 
blood glucose levels were calculated using WinNonLin program (Version 5.2.1, Pharsight Corporation, 
Cary, NC, USA). Maximum observed peak blood glucose level (Cmax) and the time at which it is 
observed (Tmax) were determined based on the observed data. Area under the blood glucose-time curve 
up to the last sampled time-point (AUClast) was estimated by the trapezoidal rule. 
3.10. Animal and Study Design 
In this study, five SD rats were used under each condition. The animals were housed in individual 
cages in a room with a 12 h light/dark cycle (lights on from 06:00 h) with 50 ±  7% relative humidity. 
All rats were adapted to a meal-feeding schedule of free access to Pico 5053 diet (Table 4) (Oriental 
Bio. Co., Seongnam, Korea) with or without samples for 2 weeks. The experimental protocols were Int. J. Mol. Sci. 2011, 12                       
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approved by the Institutional Animal Care and Use Committee (IACUC) of the Hannam University 
(Approval number: HNU2011-01). The rats had free access to tap water throughout the experiment. 
The rats were anesthetized with pentobarbital and killed, and blood was collected. The small intestine 
was cut transversely into three segments (upper, middle, and lower part) of roughly equal length. Each 
segment was flushed with ice-cold phosphate buffered saline, frozen in liquid nitrogen, and stored at 
−70 °C  for measurement of enzyme activities. 
3.11. Statistical Analysis 
All data are presented as mean   SD. Statistical analyses were carried out using  the statistical 
package SPSS (Statistical Package for Social Science, SPSS Inc., Chicago, IL, USA) program and 
significance  of  each  group  was  verified  with  the  analysis  of  One-way  ANOVA  followed  by  the 
Duncan’s test of p < 0.05. 
4. Conclusions 
The modern calorie-dense, nutrient-poor diet of processed foods, especially when combined with a 
sedentary lifestyle and abdominal obesity, produces exaggerated postprandial increase in glucose and 
lipids,  which  leads  to  inflammation  and  atherosclerosis  [3].  High-calorie  meals  rich  in  processed, 
easily digestible, quickly absorbable foods and drinks can lead to exaggerated postprandial elevations 
in blood glucose and triglycerides [3]. 
In contrast, a diet high in minimally processed, high-fiber, plant-based foods such as low glycemic 
index  vegetables  and  fruits,  whole  grains,  legumes,  and  nuts  will  markedly  blunt  the  post-meal 
increase  in  glucose.  Indeed  modern  studies  indicate  that  vinegar  significantly  reduces  post-meal 
glycemia,  probably  because  acetic  acid  slows  gastric  emptying  and  thus  delays  carbohydrate 
absorption and improves satiety [27]. Improvements in diet exert profound and immediate favorable 
changes in the postprandial dysmetabolism.  
EOS has a blood glucose lowering effect and high content of quercetin antioxidant and therefore 
has the potential to contribute to the reduction of hyperglycemia and oxidative stress-induced diabetic 
complications. These results show the positive effects of EOS against postprandial spikes in blood 
glucose resulting from high sucrose ingestion and absorption and demonstrate that the observed effect 
is not solely quercetin-dependent. Furthermore, our findings suggest that EOS with high blood glucose 
lowering effect may be due to delaying absorption of glucose through inhibition of sucrase in the 
intestinal tract. 
These in vitro and in vivo studies therefore could provide the biochemical rationale for the benefit 
of onion-based dietary supplement and the basis for further clinical study.  
Until today, quercetin was considered the most bioactive compound of onion skin. This research 
suggested  that  although  quercetin  does  have  blood  glucose  lowering  potential  via  α-glucosidase 
inhibition,  there  are  other  bioactive  compounds  present  in  onion  skin  that  contribute  towards  the 
observed bioactivities for type 2 diabetes management. Although, in this study, we provided evidence 
for  EOS  as  a  α-glucosidase  inhibitor  and  its  properties  to  decrease  blood  glucose,  such  detailed 
relationship between EOS and the expression of SI complex is not yet clear. Therefore, to provide  Int. J. Mol. Sci. 2011, 12                       
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the  precise  mechanism  based  on  a  single  compound,  further  pharmacological  and  genetic  studies  
are needed. 
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